
A revolutionary treatment for radiation poisoning may be on the horizon, as threats of nuclear warfare continue to reverberate from Moscow.
Pluri Inc. (NASDAQ:PLUR), an Israeli biotechnology company specializing in cell expansion, on Tuesday announced a new partnership with U.S. health and military agencies to continue developing the company’s PLX-R18 cell therapy as a treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), which can result from exposure to nuclear fallout. The National Institute of Allergy and Infectious Diseases (NIAID) awarded Pluri and the Department of Defense’s Armed Forces Radiobiology Research Institute (AFRRI) a contract worth $4.2 million in total to advance the potential breakthrough cell therapy.